Market Feedback of Lenalidomide
Lenalidomide has been reported the following adverse drug reactions after its global launch.
2.Toxic epidermal necrolysis
3.Tumor lysis syndrome (TLS)
4.Tumor flare reaction
6.Transient liver dysfunction
7.Hyperthyroidism and Hypothyroidism
It is difficult to reliably evaluate its incidence or establish a causal relationship with drug exposure considering the reports which come from a spontaneous report of unknown population size. However, it is necessary to account for liver insufficiency and thyroid function.
Patients treated with Lenalidomide have reported cases of transient liver dysfunction(mainly transaminases). Once this condition is encountered, please stop the treatment. Make sure that you will not take lenalidomide unless the abnormal value returns to the baseline level. Some patients did not report any increase in liver laboratory test values after they resumed treatment. Besides, there are several unknown frequency liver diseases that have been reported. It is as follows:
Thyroid Function of Lenalidomide
1.Acute liver failure and cholestasis(Both are potentially lethal)
4.Mixed cytotoxicity/Cholestatic hepatitis
There have been reports of hypothyroidism and hyperthyroidism. Before receiving the treatment, it is recommended that the state of the accompanying disease be optimally controlled. It will be better that thyroid function is monitored during the treatment.